Shots:
- Eli Lilly to acquire Scorpion, plus its leading asset STX-478, for ~2.5B in cash, incl. upfront, regulatory & sales milestones through a definitive agreement
- As per the terms, Scorpion will form an independent company owned by its current shareholders with Lilly’s minority stake to hold its employees & non-PI3Kα pipeline assets
- STX-478 (oral, QD) inhibits mutated PI3Kα forms & is currently subjected to P-I/II studies for the treatment of HR+ve breast cancer & other advanced solid tumors
Ref: PRnewswire | Image: Scorpion Therapeutics | Press Release
Related News:- Eli Lilly Reports Topline P-III (ATTAIN-MAINTAIN) Trial Results of Orforglipron for Weight Loss Maintenance
PharmaShots, your go-to media platform for customized news ranging from multiple indications. For more information, connect with us at connect@pharmashots.com
